Scammell et al. [159] suggested that chronic loss of hypocretin signaling provides no protection against Alzheimer’s disease, implying that normal levels of hypocretin are not required in the pathogenesis of the disease [160]. This evidence concerns the gene HCRT and early-onset autosomal dominant Alzheimer disease.